View More Recent Stories
-
Amicus Therapeutics (FOLD) Announces Settlement of Galafold Patent Litigation with Teva (TEVA)
-
BMO Capital on Exelixis (EXEL): 'we do not expect a cabo generic entry by MSN until at least the latest...'
-
Morgan Stanley Out Mixed on Exelixis (EXEL), PT Raised to $30, 'ruling is short of a home run scenario'
-
Immuneering Corporation (IMRX) Granted Orphan Drug Designation for IMM-1-104
-
Teva Pharma (TEVA) reports TVB-009P Accepted for Review by U.S. FDA and EU EMA
-
BofA Securities Reiterates Buy Rating on Teva Pharma (TEVA)
-
Teva Pharma (TEVA) Launches Generic Version of Sandostatin LAR Depot in the US
-
Teva (TEVA) Set To Be Fined By Eu Antitrust Regulators In Coming Weeks For Disparaging Rival Multiple Sclerosis Medicine, Sources Say - Reuters
-
Teva Pharma (TEVA) PT Raised to $26 at UBS
-
Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)
-
10 most actionable policies if Harris wins & stock implications: Jefferies
-
Teva Pharma (TEVA) Provides Update on Pivotal Clinical Phase 3 of Investigational Olanzapine LAI and UZEDY Commercial Progress
-
Teva Pharma (TEVA) Tops Q2 EPS by 6c; raises guidance
-
10 policies if Trump wins and stock implications: Jefferies
-
Teva Pharma (TEVA) Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY SPACE Trial for Prevention of Episodic Migraine
-
Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)
-
Teva Pharma (TEVA) PT Raised to $24 at UBS
-
Argus Upgraded Teva Pharma (TEVA) to Buy
-
FTC Opens Investigation Into Teva (TEVA), Escalating Patent Fight With Pharma - Washington Post
-
Vanda Pharmaceuticals (VNDA) Reports Federal Court Allowed Vanda's HETLIOZ Patent Lawsuit to Proceed
-
Teva Pharma (TEVA) Reports new AJOVY Migraine Prevention Data
-
Teva Pharma (TEVA) Reaches Agreement With the Israel Tax Authority to Resolve 2008-2010 Litigation
-
Teva Pharma (TEVA) Launches Authorized Generic of Victoza in the US
-
Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)
-
4 small and mid-cap biopharma stocks to own according to BofA

